FindTrial
Sign In

Chemotherapy Drugs, Cancer

DRUG6 trials

Sponsors

Shaare Zedek Medical Center, Immunicom Inc, Sungkyunkwan University, Gencurix, Inc., Peking Union Medical College Hospital

Conditions

AdjuvantAdvanced Breast CancerCarcinoma, Non-Small-Cell LungEarly Hormone Receptor-positive Breast CancerEsophageal CancerExtensive-stage Small Cell Lung CancerGastroesophageal CancerImmune-Related Adverse Events

Phase 1

Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
NCT03591276
Shaare Zedek Medical CenterMetastatic Breast Cancer
Start: 2019-04-18End: 2021-06-15Target: 15Updated: 2020-10-23
A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients
NCT04004910
Immunicom IncAdvanced Breast Cancer
Start: 2019-05-31End: 2023-07-31Target: 170Updated: 2022-03-24

Unknown Phase

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
NCT04115410
Sungkyunkwan UniversityCarcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events
Start: 2020-07-01End: 2021-12-31Target: 4724Updated: 2020-05-28
Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy
RecruitingNCT04278469
Gencurix, Inc.Early Hormone Receptor-positive Breast Cancer
Start: 2019-01-11End: 2029-01-31Target: 194Updated: 2020-02-20
Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
NCT04663438
Peking Union Medical College HospitalExtensive-stage Small Cell Lung Cancer
Start: 2020-06-30End: 2021-05-30Target: 300Updated: 2020-12-11
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
RecruitingNCT04688801
The Second Hospital of Shandong UniversityAdjuvant, Esophageal Cancer, Gastroesophageal Cancer +1
Start: 2020-07-01End: 2027-12-31Target: 200Updated: 2022-11-16

Related Papers

Nanochemo-immunotherapy of ER-positive metastatic breast cancer (MBC) with PEG-liposomal doxorubicin (PLD) and pembrolizumab (PEM).
Journal of Clinical Oncology2026-05-27
253P Immunopheresis to remove soluble TNF receptors as a novel immunotherapy for patients with advanced breast cancer
ESMO Open2023-05-01
Abstract 4426: Removal of soluble TNF receptors as a novel form of immunotherapy for patients with advanced solid tumors
Cancer Research2023-04-04
Abstract CT179: Safety and effectiveness of plasmapheresis-based elimination of soluble TNFα receptors combined with chemotherapy in advanced, chemorefractory triple-negative breast cancer patients - a phase I/II study (CP7-005)
Cancer Research2022-06-15
Selective removal of soluble tumor necrosis factor receptors by apheresis as a novel immunotherapy approach for triple-negative breast cancer.
Journal of Clinical Oncology2022-06-012 citations
Abstract CT135: Extracorporeal pulldown of soluble TNFRs to unleash the activity of endogenous TNFα in chemorefractory triple-negative breast cancer patients - first-in-human experience
Cancer Research2021-07-011 citations
A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer.
Journal of Clinical Oncology2021-05-206 citations
Preliminary data on antitumor activity of extracorporeal subtraction of soluble TNFRs to unleash the activity of endogenous TNFα combined with chemotherapy in treatment-refractory, advanced, triple-negative breast cancer patients.
Journal of Clinical Oncology2021-05-201 citations